Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation

被引:3
作者
Chukwu, Chukwuma A. [1 ]
Wu, Henry H. L. [2 ]
Pullerits, Kairi [3 ]
Garland, Shona [3 ]
Middleton, Rachel [1 ]
Chinnadurai, Rajkumar [1 ,3 ]
Kalra, Philip A. [1 ,3 ]
机构
[1] Northern Care Alliance NHS Fdn Trust, Dept Renal Med, Salford M6 8HD, England
[2] Univ Sydney, Royal North Shore Hosp, Kolling Inst Med Res, Renal Res Lab, Sydney, NSW 2065, Australia
[3] Univ Manchester, Fac Biol Med & Hlth, Manchester M1 7HR, England
关键词
de novo post-transplant malignancy; kidney transplantation; immunosuppression; risk factors; outcomes; SOLID-ORGAN TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINE; CANCER-RISK; RECIPIENTS; ASSOCIATION; SURVIVAL; DISEASE; PEOPLE; BREAST; COHORT;
D O I
10.3390/jcm13071872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Post-transplant malignancy is a significant cause of morbidity and mortality following kidney transplantation often emerging after medium- to long-term follow-up. To understand the risk factors for the development of de novo post-transplant malignancy (DPTM), this study aimed to assess the incidence, risk factors, and outcomes of DPTM at a single nephrology centre over two decades. Methods: This retrospective cohort study included 963 kidney transplant recipients who underwent kidney transplantation between January 2000 and December 2020 and followed up over a median follow-up of 7.1 years (IQR 3.9-11.4). Cox regression models were used to identify the significant risk factors of DPTM development, the association of DPTM with graft survival, and mortality with a functioning graft. Results: In total, 8.1% of transplant recipients developed DPTM, and the DPTM incidence rate was 14.7 per 100 patient-years. There was a higher mean age observed in the DPTM group (53 vs. 47 years, p < 0.001). The most affected organ systems were genitourinary (32.1%), gastrointestinal (24.4%), and lymphoproliferative (20.5%). Multivariate Cox analysis identified older age at transplant (aHR 9.51, 95%CI: 2.60-34.87, p < 0.001) and pre-existing glomerulonephritis (aHR 3.27, 95%CI: 1.10-9.77, p = 0.03) as significant risk factors for DPTM. Older age was significantly associated with poorer graft survival (aHR 8.71, 95%CI: 3.77-20.20, p < 0.001). When age was excluded from the multivariate Cox model, DPTM emerged as a significant risk factor for poor survival (aHR 1.76, 95%CI: 1.17-2.63, p = 0.006). Conclusion: These findings underscore the need for tailored screening, prevention, and management strategies to address DPTM in an aging and immunosuppressed kidney transplant population.
引用
收藏
页数:16
相关论文
共 50 条
[1]   Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study [J].
Acuna, Sergio A. ;
Sutradhar, Rinku ;
Kim, S. Joseph ;
Baxter, Nancy N. .
TRANSPLANTATION, 2018, 102 (07) :1156-1164
[2]   Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis [J].
Acuna, Sergio A. ;
Huang, Johnny W. ;
Dossa, Fahima ;
Shah, Prakesh S. ;
Kim, S. Joseph ;
Baxter, Nancy N. .
TRANSPLANTATION REVIEWS, 2017, 31 (04) :240-248
[3]   Cancer risk following organ transplantation:: a nationwide cohort study in Sweden [J].
Adami, J ;
Gäbel, H ;
Lindelöf, B ;
Ekström, K ;
Rydh, B ;
Glimelius, B ;
Ekbom, A ;
Adami, HO ;
Granath, F .
BRITISH JOURNAL OF CANCER, 2003, 89 (07) :1221-1227
[4]   De Novo Malignancies after Kidney Transplantation [J].
Al-Adra, David ;
Al-Qaoud, Talal ;
Fowler, Kevin ;
Wong, Germaine .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (03) :434-443
[5]   Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant [J].
Au, Eric H. ;
Chapman, Jeremy R. ;
Craig, Jonathan C. ;
Lim, Wai H. ;
Teixeira-Pinto, Armando ;
Ullah, Shahid ;
McDonald, Stephen ;
Wong, Germaine .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (03) :471-480
[6]   Kinetics of Homeostatic Proliferation and Thymopoiesis after rATG Induction Therapy in Kidney Transplant Patients [J].
Bouvy, Anne P. ;
Kho, Marcia M. L. ;
Klepper, Mariska ;
Litjens, Nicolle H. R. ;
Betjes, Michiel G. H. ;
Weimar, Willem ;
Baan, Carla C. .
TRANSPLANTATION, 2013, 96 (10) :904-913
[7]   KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation [J].
Chadban, Steven J. ;
Ahn, Curie ;
Axelrod, David A. ;
Foster, Bethany J. ;
Kasiske, Bertram L. ;
Kher, Vijah ;
Kumar, Deepali ;
Oberbauer, Rainer ;
Pascual, Julio ;
Pilmore, Helen L. ;
Rodrigue, James R. ;
Segev, Dorry L. ;
Sheerin, Neil S. ;
Tinckam, Kathryn J. ;
Wong, Germaine ;
Knoll, Gregory A. .
TRANSPLANTATION, 2020, 104 (04) :S11-S103
[8]   Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation [J].
Cherikh, WS ;
Kauffman, HM ;
McBride, MA ;
Maghirang, J ;
Swinnen, LJ ;
Hanto, DW .
TRANSPLANTATION, 2003, 76 (09) :1289-1293
[9]   ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients [J].
Crepin, T. ;
Carron, C. ;
Roubiou, C. ;
Gaugler, B. ;
Gaiffe, E. ;
Simula-Faivre, D. ;
Ferrand, C. ;
Tiberghien, P. ;
Chalopin, J. -M. ;
Moulin, B. ;
Frimat, L. ;
Rieu, P. ;
Saas, P. ;
Ducloux, D. ;
Bamoulid, J. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (04) :1028-1038
[10]  
Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P674, DOI [10.1001/jama.2018.11365, 10.1001/jama.2018.10897, 10.1097/01.ogx.0000549540.69362.81]